Eli Lilly and Company News Releases

Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study

- Results from two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth across both baricitinib dosing groups, compared to placebo - Program data will support a submission to achieve a potential first-in-disease regulatory approval - Safety profile is
favicon
investor.lilly.com
investor.lilly.com